MX2016007865A - Peptidos citotoxicos y conjugados de los mismos. - Google Patents
Peptidos citotoxicos y conjugados de los mismos.Info
- Publication number
- MX2016007865A MX2016007865A MX2016007865A MX2016007865A MX2016007865A MX 2016007865 A MX2016007865 A MX 2016007865A MX 2016007865 A MX2016007865 A MX 2016007865A MX 2016007865 A MX2016007865 A MX 2016007865A MX 2016007865 A MX2016007865 A MX 2016007865A
- Authority
- MX
- Mexico
- Prior art keywords
- immunoconjugates
- peptides
- compositions
- conjugates
- formula
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 231100000433 cytotoxic Toxicity 0.000 title abstract 3
- 230000001472 cytotoxic effect Effects 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 229940127121 immunoconjugate Drugs 0.000 abstract 6
- 239000000611 antibody drug conjugate Substances 0.000 abstract 2
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361917293P | 2013-12-17 | 2013-12-17 | |
| PCT/US2014/070800 WO2015095301A2 (en) | 2013-12-17 | 2014-12-17 | Cytotoxic peptides and conjugates thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016007865A true MX2016007865A (es) | 2017-01-11 |
Family
ID=52463118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016007865A MX2016007865A (es) | 2013-12-17 | 2014-12-17 | Peptidos citotoxicos y conjugados de los mismos. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9988420B2 (enExample) |
| EP (2) | EP3082877B1 (enExample) |
| JP (2) | JP6636925B2 (enExample) |
| KR (1) | KR20160098257A (enExample) |
| CN (1) | CN105899526A (enExample) |
| AU (1) | AU2014364812B2 (enExample) |
| BR (1) | BR112016012538A2 (enExample) |
| CA (1) | CA2930614A1 (enExample) |
| EA (1) | EA201691251A1 (enExample) |
| ES (1) | ES2758506T3 (enExample) |
| IL (1) | IL245558B (enExample) |
| MX (1) | MX2016007865A (enExample) |
| PL (1) | PL3082877T3 (enExample) |
| PT (1) | PT3082877T (enExample) |
| SG (1) | SG11201604877UA (enExample) |
| WO (1) | WO2015095301A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2874493T3 (es) * | 2013-02-08 | 2021-11-05 | Novartis Ag | Sitios específicos para modificar anticuerpos para generar inmunoconjugados |
| MX368258B (es) | 2013-03-15 | 2019-09-25 | Zymeworks Inc | Compuestos citotoxicos y antimitoticos y metodos de uso de los mismos. |
| BR112016015105A8 (pt) | 2013-12-27 | 2018-04-24 | Var2 Pharmaceuticals Aps | conjugados var2csa-droga |
| KR102384740B1 (ko) | 2013-12-27 | 2022-04-07 | 자임워크스 인코포레이티드 | 약물 접합체를 위한 설폰아마이드-함유 연결 시스템 |
| WO2015138615A2 (en) * | 2014-03-12 | 2015-09-17 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
| CN106573956A (zh) | 2014-06-13 | 2017-04-19 | 诺华股份有限公司 | 澳瑞他汀衍生物及其缀合物 |
| AU2015318556C1 (en) | 2014-09-17 | 2021-01-07 | Zymeworks Bc Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| JP6987424B2 (ja) | 2016-05-11 | 2022-01-05 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックスを洗浄および／または消毒する方法 |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| CN109071613A (zh) | 2016-05-11 | 2018-12-21 | 通用电气医疗集团生物工艺研发股份公司 | 分离基质 |
| CN109311949B (zh) | 2016-05-11 | 2022-09-16 | 思拓凡生物工艺研发有限公司 | 储存分离基质的方法 |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| US10517958B2 (en) | 2016-10-04 | 2019-12-31 | Zymeworks Inc. | Compositions and methods for the treatment of platinum-drug resistant cancer |
| JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
| UY38265A (es) * | 2018-06-20 | 2020-01-31 | Novartis Ag | Conjugados anticuerpo droga para ablación de células madre hematopoyéticas |
| US20220017462A1 (en) * | 2018-11-23 | 2022-01-20 | WuXi Biologics Ireland Limited | Ortho-phthalaldehyde containing linkers and use for preparation of antibody-drug conjugate |
| BR112022018002A2 (pt) * | 2020-03-09 | 2022-11-08 | Sigma Aldrich Co Llc | Preparação eficiente de análogos de dolastatina e auristatina por meio de um intermediário comum |
| US20230181756A1 (en) | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
| AU2022207278A1 (en) * | 2021-01-18 | 2023-08-03 | Ajinomoto Co., Inc. | Compound or salt thereof, and antibody obtained therefrom |
| WO2023061405A1 (zh) * | 2021-10-12 | 2023-04-20 | 成都科岭源医药技术有限公司 | 一种高稳定性的靶向接头-药物偶联物 |
| US20240108744A1 (en) * | 2022-07-27 | 2024-04-04 | Mediboston Limited | Auristatin derivatives and conjugates thereof |
| WO2024152000A1 (en) * | 2023-01-13 | 2024-07-18 | The Trustees Of The University Of Pennsylvania | Disruptable linker compositions, switchable bispecific t cell nanoengager (switch-bite) compositions comprising the same, and methods of use thereof |
| AU2024258642A1 (en) | 2023-04-18 | 2025-12-04 | Astrazeneca Ab | Conjugates comprising cleavable linkers |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| SG87056A1 (en) | 1991-08-09 | 2002-03-19 | Teikoku Hormone Mfg Co Ltd | Novel tetrapeptide derivative |
| ATE282630T1 (de) | 1993-10-01 | 2004-12-15 | Teikoku Hormone Mfg Co Ltd | Dolastatin-derivate |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| PT831100E (pt) | 1995-04-21 | 2001-01-31 | Teikoku Hormone Mfg Co Ltd | Novos derivados de peptido |
| EP2380906A2 (en) | 1997-06-12 | 2011-10-26 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| US7803915B2 (en) | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| PL2489364T3 (pl) | 2003-11-06 | 2015-06-30 | Seattle Genetics Inc | Związki monometylowaliny zdolne do sprzęgania do przeciwciał |
| ES2715776T3 (es) * | 2004-11-12 | 2019-06-06 | Seattle Genetics Inc | Auristatinas que tienen una unidad de ácido aminobenzoico en el extremo N |
| EP1817341A2 (en) | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| BRPI0612529A2 (pt) | 2005-06-20 | 2010-11-23 | Psma Dev Company Llc | conjugados de anticorpo-medicamento de psma |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| WO2007103288A2 (en) | 2006-03-02 | 2007-09-13 | Seattle Genetics, Inc. | Engineered antibody drug conjugates |
| AR059900A1 (es) | 2006-03-17 | 2008-05-07 | Genentech Inc | Anticuerpos anti-tat226 e inmunoconjugados |
| PT2211904T (pt) | 2007-10-19 | 2016-11-02 | Seattle Genetics Inc | Agentes de ligação a cd19 e seus usos |
| ES2647927T3 (es) | 2008-03-18 | 2017-12-27 | Seattle Genetics, Inc. | Conjugados enlazadores del fármaco auriestatina |
| WO2012041805A1 (de) | 2010-09-29 | 2012-04-05 | Bayer Pharma Aktiengesellschaft | N-carboxyalkyl-auristatine und ihre verwendung |
| ES2730941T7 (es) | 2010-10-22 | 2020-05-27 | Seattle Genetics Inc | Efectos sinérgicos entre los conjugados de conjugados anticuerpo-fármaco a base de auristatina e inhibidores de la ruta PI3K-AKT-mTOR |
| WO2012113847A1 (en) | 2011-02-25 | 2012-08-30 | Lonza Ltd | Branched linker for protein drug conjugates |
| WO2012123423A1 (de) | 2011-03-16 | 2012-09-20 | Bayer Pharma Aktiengesellschaft | N-carboxyalkyl-auristatine und ihre verwendung |
| US20130066055A1 (en) | 2011-04-21 | 2013-03-14 | Bayer Intellectual Property Gmbh | New binder-drug conjugates (adcs) and use thereof |
| KR102356286B1 (ko) | 2011-05-27 | 2022-02-08 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
| SI2780039T1 (en) | 2011-11-17 | 2018-06-29 | Pfizer Inc. | Cytotoxic peptides and their conjugates between the antibody and the drug |
| JP2015502397A (ja) * | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
| AU2013271952A1 (en) * | 2012-06-04 | 2014-11-13 | Irm Llc | Site-specific labeling methods and molecules produced thereby |
| ES2874493T3 (es) * | 2013-02-08 | 2021-11-05 | Novartis Ag | Sitios específicos para modificar anticuerpos para generar inmunoconjugados |
-
2014
- 2014-12-17 KR KR1020167015935A patent/KR20160098257A/ko not_active Ceased
- 2014-12-17 BR BR112016012538A patent/BR112016012538A2/pt not_active Application Discontinuation
- 2014-12-17 AU AU2014364812A patent/AU2014364812B2/en not_active Ceased
- 2014-12-17 EP EP14835606.6A patent/EP3082877B1/en not_active Not-in-force
- 2014-12-17 EP EP19193628.5A patent/EP3753578A1/en not_active Withdrawn
- 2014-12-17 CN CN201480068696.XA patent/CN105899526A/zh active Pending
- 2014-12-17 SG SG11201604877UA patent/SG11201604877UA/en unknown
- 2014-12-17 MX MX2016007865A patent/MX2016007865A/es active IP Right Grant
- 2014-12-17 ES ES14835606T patent/ES2758506T3/es active Active
- 2014-12-17 WO PCT/US2014/070800 patent/WO2015095301A2/en not_active Ceased
- 2014-12-17 US US15/104,727 patent/US9988420B2/en active Active
- 2014-12-17 JP JP2016540522A patent/JP6636925B2/ja not_active Expired - Fee Related
- 2014-12-17 EA EA201691251A patent/EA201691251A1/ru unknown
- 2014-12-17 PL PL14835606T patent/PL3082877T3/pl unknown
- 2014-12-17 CA CA2930614A patent/CA2930614A1/en not_active Abandoned
- 2014-12-17 PT PT148356066T patent/PT3082877T/pt unknown
-
2016
- 2016-05-09 IL IL245558A patent/IL245558B/en not_active IP Right Cessation
-
2018
- 2018-04-24 US US15/961,531 patent/US10392421B2/en active Active
-
2019
- 2019-06-12 US US16/439,204 patent/US10787480B2/en active Active
- 2019-09-27 JP JP2019176561A patent/JP2020023514A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US9988420B2 (en) | 2018-06-05 |
| US10787480B2 (en) | 2020-09-29 |
| AU2014364812B2 (en) | 2017-05-25 |
| EP3082877A2 (en) | 2016-10-26 |
| JP2020023514A (ja) | 2020-02-13 |
| ES2758506T3 (es) | 2020-05-05 |
| PT3082877T (pt) | 2019-12-03 |
| CA2930614A1 (en) | 2015-06-25 |
| AU2014364812A1 (en) | 2016-07-07 |
| BR112016012538A2 (pt) | 2017-09-26 |
| EA201691251A1 (ru) | 2016-11-30 |
| EP3082877B1 (en) | 2019-08-28 |
| CN105899526A (zh) | 2016-08-24 |
| JP2017503777A (ja) | 2017-02-02 |
| US20180244717A1 (en) | 2018-08-30 |
| SG11201604877UA (en) | 2016-07-28 |
| IL245558A0 (en) | 2016-06-30 |
| PL3082877T3 (pl) | 2020-02-28 |
| US20190382441A1 (en) | 2019-12-19 |
| JP6636925B2 (ja) | 2020-01-29 |
| WO2015095301A2 (en) | 2015-06-25 |
| US20160311853A1 (en) | 2016-10-27 |
| US10392421B2 (en) | 2019-08-27 |
| WO2015095301A3 (en) | 2015-09-03 |
| KR20160098257A (ko) | 2016-08-18 |
| EP3753578A1 (en) | 2020-12-23 |
| IL245558B (en) | 2020-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016007865A (es) | Peptidos citotoxicos y conjugados de los mismos. | |
| MX2016016515A (es) | Derivados de auristatina y conjugados de los mismos. | |
| CL2016000468A1 (es) | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso. | |
| CY1122161T1 (el) | Συζευγμενα αντισωματα anti-cd38 | |
| PH12014501039B1 (en) | Cytotoxic peptides and antibody drug conjugates thereof | |
| PH12019501330A1 (en) | Antibody drug conjugates for ablating hematopoietic stem cells | |
| PH12016501171A1 (en) | Peptidomimetic compounds and antibody-drug conjugates thereof | |
| UA110370C2 (en) | Conjugates of amatoxin with improved linkages | |
| MX350200B (es) | Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74. | |
| EA201691059A1 (ru) | Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство | |
| MX366503B (es) | Derivados de amatoxina. | |
| TN2015000396A1 (en) | Antibody drug conjugates | |
| MX361218B (es) | Análogos de spliceostatina. | |
| EA201491441A1 (ru) | Композиции конъюгата xten и способы их получения | |
| NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
| NZ725131A (en) | Tubulysin derivatives | |
| IN2014CN04961A (enExample) | ||
| MY169147A (en) | Drug-protein conjugates | |
| EA202090741A1 (ru) | Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака | |
| EA201500506A1 (ru) | КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16a | |
| WO2014172309A3 (en) | Therapeutic compositions for neutralizing type i interferons, and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |